RevBio (formerly LaunchPad Medical)
2 known investors
RevBio develops TETRANITE, a synthetic, bioengineered regenerative bone adhesive that transitions from a putty to a cement-like scaffold to bond bone-to-bone and bone-to-metal in wet-field surgical settings. The biomaterial targets neurosurgical, orthopaedic, dental, and animal health applications such as cranial flap fixation, dental implant stabilization, bone grafting, and fracture repair.</parameter> <parameter name="hq_city">Lowell
Investors · 2
Non-dilutive funding · 8 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $375K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2018 | $197.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.